{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-22-003391","form_type":"8-K","ticker":"PHIO","cik":"0001533040","company_name":"Phio Pharmaceuticals Corp.","filed_at":"2022-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.100682+00:00","generated_at":"2026-06-25T21:38:40.110159+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Phio Pharmaceuticals CEO Gerrit Dispersyn departs; Geert Cauwenbergh appointed interim CEO/CFO","bullets":["President and CEO Gerrit Dispersyn left the company effective May 5, 2022; board reduced from eight to seven.","Dispersyn to receive six months base salary severance plus six months medical/dental premium contributions.","Director Geert Cauwenbergh appointed interim principal executive and financial officer effective May 5, 2022.","Cauwenbergh previously served as Phio CEO from 2012 to 2019; will receive $7,500 monthly cash payment."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-22-003391","json":"https://secwatch.observer/filing/0001683168-22-003391.json","markdown":"https://secwatch.observer/filing/0001683168-22-003391.md","text":"https://secwatch.observer/filing/0001683168-22-003391.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533040/000168316822003391/0001683168-22-003391-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533040/000168316822003391/phio_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:38:40.110159+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"84e28e13bf","claim":"Gerrit Dispersyn departed as President and Chief Executive Officer at Phio Pharmaceuticals Corp..","evidence_excerpt":"On May 5, 2022, Phio Pharmaceuticals Corp. (the “Company”) announced the departure of Gerrit Dispersyn, Dr. Med. Sc., from his role as President and Chief Executive Officer of the Company, effective as of May 5, 2022","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533040/000168316822003391/0001683168-22-003391-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"93060b6b9f","claim":"Geert Cauwenbergh was appointed as Principal Executive and Financial Officer at Phio Pharmaceuticals Corp..","evidence_excerpt":"On May 4, 2022, the Board appointed Geert Cauwenbergh, Dr. Med. Sc., as the Company’s interim principal executive and financial officer, effective as of May 5, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533040/000168316822003391/0001683168-22-003391-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Principal Executive and Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}